Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
Conference Details:
Presentation: |
|
Format : |
In-person and virtual |
Location: |
Sofitel |
Conference attendance : |
Register on the conference website |
Livestream: |
Register here |
1x1 meetings: |
Upon request by registered investors |
About
Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 Pivotal superiority trial of Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. A Biologics License Application for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma, is currently under review by the FDA with
Investor Contact:
ir@citiuspharma.com
908-967-6677 x113
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-ld-micro-invitational-xiv-investor-conference-302108125.html
SOURCE